> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Merck Verquvo for Heart Failure
- URL: https://www.fdaweb.com/fda-approves-merck-verquvo-for-heart-failure/
- Published: 2021-01-20T12:00:00.000Z
- Updated: 2026-09-14T16:43:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148486

FDA has approved Merck’s Verquvo (vericiguat), a soluble guanylate cyclase stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. Merck [says](http://www.marketwatch.com/story/merck-announces-us-fda-approval-of-verquvo-vericiguat-2021-01-20?ref=fdaweb.com) the approval is based on the results of the pivotal Phase 3 VICTORIA trial and follows a priority review. It reports that in the trial Verquvo was found to be superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization based on a time-to-event analysis.

The drug contains a Boxed Warning indicating that Verquvo should not be administered to pregnant females because it may cause fetal harm.